An NMR-based serum test has been shown to assess kidney function and provides for a more precise estimation of glomerular filtration rate.
The nuclear magnetic resonance (NMR) diagnostics company numares has published data showing that its novel, multi-marker approach to assess kidney function allowed for a more precise estimation of glomerular filtration rate (GFR) by a simple serum test. Named GFRNMR, the test provides metabolic characterisation of renal dysfunction by evaluating a group of metabolites. This “metabolite constellation” is comprised of myo-inositol, dimethylsulfone, valine and creatinine, and is independent of age and sex. The test holds the potential for an improved assessment of kidney function, and deeper insights into kidney pathophysiology.
In a proof-of-concept study it was shown that a combination of multiple renal biomarkers, all with pathophysiological relevance, may overcome the diagnostic limitations of existing methods used to estimate GFR. This is a measure of kidney function used for assessment of metabolic renal dysfunction associated with chronic kidney disease.
